Edgestream Partners L.P. Makes New $5.44 Million Investment in DaVita Inc. (NYSE:DVA)

Edgestream Partners L.P. purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 33,188 shares of the company's stock, valued at approximately $5,441,000.

Several other institutional investors and hedge funds have also modified their holdings of DVA. Transcendent Capital Group LLC acquired a new position in shares of DaVita during the third quarter worth approximately $25,000. Blue Trust Inc. boosted its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. acquired a new stake in DaVita in the 2nd quarter worth $43,000. Versant Capital Management Inc increased its holdings in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company's stock worth $45,000 after purchasing an additional 155 shares during the period. Finally, Friedenthal Financial acquired a new position in shares of DaVita during the second quarter valued at about $48,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Price Performance

Shares of NYSE DVA traded up $0.54 during midday trading on Friday, reaching $166.17. 314,276 shares of the company traded hands, compared to its average volume of 828,300. DaVita Inc. has a 12 month low of $99.18 and a 12 month high of $169.51. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The stock's 50-day simple moving average is $158.57 and its 200-day simple moving average is $149.39. The firm has a market cap of $13.63 billion, a PE ratio of 17.93, a PEG ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.85 earnings per share. As a group, equities analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on DVA shares. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. UBS Group upped their target price on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Finally, Truist Financial increased their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus price target of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.